Xconomy Forum: Biotech in the Belt-Tightening Era

Payers didn’t have much power in biotech’s old days. Back then, biotech companies that offered patients important new drugs, devices or diagnostics could essentially impose high prices on U.S. health insurers. Getting data to win over the FDA, physicians, and shareholders was what counted. But payers are becoming increasingly powerful, as the Affordable Care Act heads toward full implementation, and employers everywhere are pushing for an end to runaway healthcare spending. Life science investors now increasingly want to know how the new products in the pipeline of today will thrive in the cost-constrained environment of tomorrow. Join Xconomy for a series of chats with biotech and healthcare economics leaders who are seeking products that add meaningful value to the healthcare system, not just more cost.